Cite
HARVARD Citation
Thaci, D. et al. (2021). Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). British journal of dermatology. pp. 323-334. [Online].